Castle Biosciences Profit Margin 2019-2021 | CSTL

Current and historical gross margin, operating margin and net profit margin for Castle Biosciences (CSTL) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Castle Biosciences net profit margin as of June 30, 2021 is -28.88%.
Castle Biosciences Annual Profit Margins
Castle Biosciences Quarterly Profit Margins
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.701B $0.063B
Castle Biosciences Inc. is a commercial-stage dermatological cancer company. It is focused on providing physicians and patients, clinically actionable genomic information. Castle Biosciences Inc. is based in Texas, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.972B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $11.985B 20.30
Biohaven Pharmaceutical Holding (BHVN) United States $8.378B 0.00
Emergent Biosolutions (EBS) United States $2.740B 6.61
Arcus Biosciences (RCUS) United States $2.509B 0.00
Myovant Sciences (MYOV) United Kingdom $1.869B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.763B 0.00
Zymeworks (ZYME) Canada $1.061B 0.00
Ambrx Biopharma (AMAM) United States $0.501B 0.00
SQZ Biotechnologies (SQZ) United States $0.333B 0.00
Enzo Biochem (ENZ) United States $0.157B 15.43